Table 1

Characteristics of the study population

Total subjects
N=570
Study follow-up time (years), median (IQR)5.5 (3.8–5.7)
No./patient over study period, median (IQR)
 iPExs0 (0–2)
 oPExs4 (2–7)
Rate of oPEx/patient/year, median (IQR)0.9 (0.5–1.5)
Minimum time (days) between
 Consecutive oPEx, median (IQR)150 (63–324)
 oPEx and iPEx, median (IQR)56 (21–184)
Female, n (%)266 (46.7)
Age at diagnosis (years), n (%)
 ≤2359 (63.0)
 >2211 (37.0)
Age*, median (IQR)21 (11.5–32.9)
CFTR functional class, n (%)
 I–III463 (81.2)
 IV–V77 (13.5)
Missing30 (5.3)
Pancreatic insufficient, n (%)441 (77.4)
CFRD*, n (%)71 (12.5)
FEV1% predicted*, median (IQR)72% (51.9%–89.2%)
BMI Z-score, mean (SD)−0.1 (1.1)
Positive culture†, n (%)
Stenotrophomonas maltophilia27 (4.8)
Burkholderia cepacia complex54 (9.6)
Staphylococcus aureus147 (26.2)
Haemophilus influenzae12 (2.14)
Aspergillus species97 (17.3)
 MRSA9 (1.6)
Achromobacter xylosoxidans9 (1.6)
Pseudomonas aeruginosa
  Never151 (26.9)
  Intermittent302 (53.7)
  Chronic109 (19.4)
  • *At each subject's first observation in the study period.

  • †Based on a positive culture or P. aeruginosa culture status (never, intermittent, chronic, as per Leed's criteria) in the 12 months prior to entry into the study cohort; eight patients were missing microbiology data.

  • BMI, body mass index; CFRD, cystic fibrosis-related diabetes; CFTR, CF transmembrane conductance regulator; FEV1% pred, FEV1 % predicted; MRSA, methicillin-resistant S. aureus.